Clopidogrel and thrombotic thrombocytopenic purpura: No clear case for causality
Navneet S. Majhail, MBBS, MD
Department of Internal Medicine, The Cleveland Clinic
Alan E. Lichtin, MD
Department of Hematology and Medical Oncology, The Cleveland Clinic
Address: Alan E. Lichtin, MD, Department of Hematology and Medical Oncology, R35, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: email@example.com
ABSTRACTAlthough the antiplatelet agent clopidogrel is associated with an increased incidence of thrombotic thrombocytopenic purpura (TTP), available evidence is not sufficient to establish or disprove a causal relationship. We review and assess the evidence and case reports linking clopidogrel use with TTP and discuss how to approach the risk of TTP in patients taking clopidogrel.